Pfizer Net Income 2006-2018 | PFE

Pfizer annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Pfizer net income for the quarter ending September 30, 2018 was $4.114B, a 44.86% increase year-over-year.
  • Pfizer net income for the twelve months ending September 30, 2018 was $23.821B, a 142.85% increase year-over-year.
  • Pfizer annual net income for 2017 was $21.308B, a 195.33% increase from 2016.
  • Pfizer annual net income for 2016 was $7.215B, a 3.66% increase from 2015.
  • Pfizer annual net income for 2015 was $6.96B, a 23.81% decline from 2014.
Pfizer Annual Net Income
(Millions of US $)
2017 $21,308
2016 $7,215
2015 $6,960
2014 $9,135
2013 $22,003
2012 $14,570
2011 $10,009
2010 $8,257
2009 $8,635
2008 $8,104
2007 $8,144
2006 $19,337
2005 $8,085
Pfizer Quarterly Net Income
(Millions of US $)
Q3 2018 $4,114
Q2 2018 $3,872
Q1 2018 $3,561
Q4 2017 $12,274
Q3 2017 $2,840
Q2 2017 $3,073
Q1 2017 $3,121
Q4 2016 $775
Q3 2016 $1,355
Q2 2016 $2,047
Q1 2016 $3,038
Q4 2015 $-172
Q3 2015 $2,130
Q2 2015 $2,626
Q1 2015 $2,376
Q4 2014 $1,228
Q3 2014 $2,666
Q2 2014 $2,912
Q1 2014 $2,329
Q4 2013 $2,568
Q3 2013 $2,590
Q2 2013 $14,095
Q1 2013 $2,750
Q4 2012 $6,315
Q3 2012 $3,208
Q2 2012 $3,253
Q1 2012 $1,794
Q4 2011 $1,439
Q3 2011 $3,738
Q2 2011 $2,610
Q1 2011 $2,222
Q4 2010 $2,890
Q3 2010 $866
Q2 2010 $2,475
Q1 2010 $2,026
Q4 2009 $767
Q3 2009 $2,878
Q2 2009 $2,261
Q1 2009 $2,729
Q4 2008 $266
Q3 2008 $2,278
Q2 2008 $2,776
Q1 2008 $2,784
Q4 2007 $2,724
Q3 2007 $761
Q2 2007 $1,267
Q1 2007 $3,392
Q4 2006 $9,449
Q3 2006 $3,362
Q2 2006 $2,415
Q1 2006 $4,111
Q4 2005 $2,732
Q3 2005 $1,589
Q2 2005 $3,463
Q1 2005 $301
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $259.069B $52.546B
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14